Mishra R, Nielsen B, Trudrung M, Lee S, Bolstad L, Hellenbrand D
Cells. 2024; 13(18).
PMID: 39329731
PMC: 11430430.
DOI: 10.3390/cells13181547.
Nawaz S, Kulyar M, Mo Q, Yao W, Iqbal M, Li J
Animals (Basel). 2023; 13(24).
PMID: 38136788
PMC: 10740744.
DOI: 10.3390/ani13243750.
Luthfiana D, Utomo D
In Silico Pharmacol. 2023; 11(1):23.
PMID: 37719716
PMC: 10504231.
DOI: 10.1007/s40203-023-00161-5.
Augoff K, Hryniewicz-Jankowska A, Tabola R, Stach K
Cancers (Basel). 2022; 14(7).
PMID: 35406619
PMC: 8998077.
DOI: 10.3390/cancers14071847.
Charzewski L, Krzysko K, Lesyng B
Sci Rep. 2021; 11(1):13376.
PMID: 34183752
PMC: 8238946.
DOI: 10.1038/s41598-021-92881-x.
Bioguided Fractionation of Local Plants against Matrix Metalloproteinase9 and Its Cytotoxicity against Breast Cancer Cell Models: In Silico and In Vitro Study (Part II).
Hariono M, Rollando R, Yoga I, Harjono A, Suryodanindro A, Yanuar M
Molecules. 2021; 26(5).
PMID: 33800366
PMC: 7962846.
DOI: 10.3390/molecules26051464.
Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy.
Yosef G, Hayun H, Papo N
Biochem J. 2021; 478(5):1139-1157.
PMID: 33600567
PMC: 7959692.
DOI: 10.1042/BCJ20200628.
The Pharmacological TAILS of Matrix Metalloproteinases and Their Inhibitors.
Das N, Benko C, Gill S, Dufour A
Pharmaceuticals (Basel). 2021; 14(1).
PMID: 33396445
PMC: 7823758.
DOI: 10.3390/ph14010031.
Bioguided Fractionation of Local Plants against Matrix Metalloproteinase9 and Its Cytotoxicity against Breast Cancer Cell Models: In Silico and In Vitro Study.
Hariono M, Rollando R, Karamoy J, Hariyono P, Atmono M, Djohan M
Molecules. 2020; 25(20).
PMID: 33066411
PMC: 7587335.
DOI: 10.3390/molecules25204691.
Calcium and hydroxyapatite binding site of human vitronectin provides insights to abnormal deposit formation.
Shin K, Kent J, Singh C, Fujimoto L, Yu J, Tian Y
Proc Natl Acad Sci U S A. 2020; 117(31):18504-18510.
PMID: 32699145
PMC: 7414086.
DOI: 10.1073/pnas.2007699117.
Molecular Interactions Stabilizing the Promatrix Metalloprotease-9·Serglycin Heteromer.
Dawadi R, Malla N, Hegge B, Wushur I, Berg E, Svineng G
Int J Mol Sci. 2020; 21(12).
PMID: 32545641
PMC: 7352350.
DOI: 10.3390/ijms21124205.
Inhibiting Matrix Metalloproteinase-2 Activation by Perturbing Protein-Protein Interactions Using a Cyclic Peptide.
Sarkar P, Li Z, Ren W, Wang S, Shao S, Sun J
J Med Chem. 2020; 63(13):6979-6990.
PMID: 32491863
PMC: 7437931.
DOI: 10.1021/acs.jmedchem.0c00180.
Recent progress in the strategic incorporation of fluorine into medicinally active compounds.
Haranahalli K, Honda T, Ojima I
J Fluor Chem. 2019; 217:29-40.
PMID: 31537946
PMC: 6752223.
DOI: 10.1016/j.jfluchem.2018.11.002.
Propeptide glycosylation and galectin-3 binding decrease proteolytic activation of human proMMP-9/progelatinase B.
Boon L, Ugarte-Berzal E, Martens E, Vandooren J, Rybakin V, Colau D
FEBS J. 2018; 286(5):930-945.
PMID: 30422384
PMC: 7379967.
DOI: 10.1111/febs.14698.
The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
Sylte I, Dawadi R, Malla N, von Hofsten S, Nguyen T, Solli A
PLoS One. 2018; 13(8):e0200237.
PMID: 30075004
PMC: 6075749.
DOI: 10.1371/journal.pone.0200237.
Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.
Triki D, Cano Contreras M, Flatters D, Visseaux B, Descamps D, Camproux A
Sci Rep. 2018; 8(1):710.
PMID: 29335428
PMC: 5768731.
DOI: 10.1038/s41598-017-18941-3.
Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell.
Hoggatt J, Singh P, Tate T, Chou B, Datari S, Fukuda S
Cell. 2017; 172(1-2):191-204.e10.
PMID: 29224778
PMC: 5812290.
DOI: 10.1016/j.cell.2017.11.003.
Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions.
Alford V, Kamath A, Ren X, Kumar K, Gan Q, Awwa M
ACS Chem Biol. 2017; 12(11):2788-2803.
PMID: 28945333
PMC: 5697452.
DOI: 10.1021/acschembio.7b00758.
Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy.
Chen J, Ren Z, Zhu M, Khalil R
Biochem Pharmacol. 2017; 138:81-95.
PMID: 28506758
PMC: 5516730.
DOI: 10.1016/j.bcp.2017.05.005.
Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.
Nuti E, Rosalia L, Cuffaro D, Camodeca C, Giacomelli C, Da Pozzo E
ACS Med Chem Lett. 2017; 8(3):293-298.
PMID: 28337319
PMC: 5346986.
DOI: 10.1021/acsmedchemlett.6b00446.